Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRK · Real-Time Price · USD
38.75
+4.26 (12.35%)
At close: Sep 26, 2025, 4:00 PM EDT
38.96
+0.21 (0.54%)
After-hours: Sep 26, 2025, 7:57 PM EDT
Scholar Rock Holding Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
128
Market Cap
3.72B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SRRK News
- 4 days ago - Scholar Rock: Despite CRL, This Is A Strong Buy With Apitegromab Expansions - Seeking Alpha
- 4 days ago - Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection - Benzinga
- 4 days ago - Firefly Aerospace Posts Q2 Results, Joins Scholar Rock And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 4 days ago - US FDA declines to approve Scholar Rock's muscle weakness drug - Reuters
- 4 days ago - FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility - Business Wire
- 15 days ago - Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment - Business Wire
- 7 weeks ago - Scholar Rock Holding Corporation (SRRK) Q2 2025 Earnings Call Transcript - Seeking Alpha